PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer

• Status: Recruiting
• Trial end date: 2021-09-30
• Target enrollment: 0
• Participant gender: Female

Summary

This trial studies how well positron emission tomography/magnetic resonance imaging (PET/MRI) scan works in checking patients with stage IA1-IB3 cervical cancer that can be removed by surgery (resectable). PET/MRI scan may help doctors learn more about the spread of the disease.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Deoxyglucose; Fluorodeoxyglucose F18

Criteria

Inclusion Criteria:

• All patients with suspected clinical stage IA1-IB3 cervical cancer except patients with tumors > 4 cm

• No contraindications to MRI

• Patients undergoing surgical procedure at MD Anderson

• Suspected cervical cancer

Exclusion Criteria:

• Patients who have contraindication to MRI

• Glomerular filtration rate (GFR) < 30

• Pregnant patients

• Patients with history of previous radiation

• Patients with previous surgery for cervical cancer, unless residual tumor noted on physical exam

• Patients with endometrial cancer extending to the cervix

• Allergic reaction to gadolinium based contrast

• Body weight of greater than 450 (181.4 kg)

• Patients requiring general sedation

• Extremely claustrophobic patients